Model-based optimal therapy for high-impact diseases by Kovács, Levente et al.
Model-based optimal therapy for high-impact 
diseases 
 
L. Kovács*, J. Sápi*, T. Ferenci*, P. Szalay**, D.A. Drexler**, Gy. Eigner*, P.I. Sas*, B. Kiss**, I. Harmati**, 
M. Kozlovszky*, Z. Sápi*** 
* Óbuda University, Budapest, Hungary  
{kovacs.levente, kozlovszky.miklos}@nik.uni-obuda.hu, {ferenci.tamas, sapi.johanna}@phd.uni-obuda.hu, 
eignergyorgy@googlemail.com, sapi35@gmail.com 
** Budapest University of Technology and Economics, Budapest, Hungary 
{szalay, drexler, harmati}@iit.bme.hu 




Abstract—The current paper represents a continuation of 
the conference papers presented at the INES 2011 and 2012 
conferences. A brief summary of the newest results in the 
field of physiological modeling and control are presented 
focusing on high public health impact diseases: diabetes, 
tumor and obesity. In the case of diabetes control, 
preliminary model-free results of the developed robust 
control framework is presented, while in the case of tumor 
control we have started to create a new tumor growth model 
based on clinical experiments. In the case of biostatistical 
investigation of obesity, new aspects of relationship between 
overweight/obesity and laboratory results was examined. 
I. INTRODUCTION 
Physiological control - a subdiscipline of biomedical 
engineering [1] - studies and applies identification and 
control strategies in order to understand and help 
automated treatment of various diseases or injuries of the 
human body. In the last period the literature focused more 
and more on individualized model-based control 
algorithms, but on the other way an important question 
has been formulated how to generalize the obtained 
results. The newly formed Physiological Controls Group 
of the Óbuda University together with the Control 
Engineering and Information Technology of the Budapest 
University of Technology and Economics and the 
Semmelweis University from Budapest are investigating 
the mentioned problem. 
The article briefly presents the newest results obtained 
as a direct continuation of the results presented at the 
INES 2011 and 2012 conferences [2], [3]. 
Diabetes is named by the World Health Organization 
(WHO) as the “disease of the future”. Statistics of the 
International Diabetes Federation (IDF) show that the 
European Region has the highest number and the highest 
incidence rate of type 1 diabetes (T1DM) in children from 
any other region worldwide [4]. 
Sensor-augmented pump therapy – using continuous 
glucose monitors (CGM) for the subcutaneous 
measurement of glucose concentration and insulin pumps 
for the subcutaneous delivery of insulin – seems to 
improve the glycaemic control compared to traditional 
therapeutic schemes [5]. 
The automatic regulation of glucose profile using a 
controller that is closing the loop between CGM and pump 
will make the realization of an AP [6]. Different control 
algorithms have been proposed in the literature [6], and 
those being able to develop a prototype system presented 
good results achieving nocturnal glucose regulation [6]. 
However, during the daytime, due to insulin sensitivity 
differences, patient variability and also other uncontrolled 
and not modeled events (like stress, physical activity, 
sensor failure, meal estimation error, etc.) the current 
approaches cannot give a robust solution; hence, the AP 
problem remains a huge challenge. 
Cancer diseases are leading causes of death nowadays 
all around the world. In the EU the total predicted number 
of cancer deaths in 2013 is 1.314.236 compared with 
1.281.694 in 2009 [7]. In Hungary, cancer was the second 
most common cause of death after cardiovascular diseases 
in 2012 [8]. 
There are classical therapies, such as chemotherapy and 
radiation therapy, but chemical agents and ionizing 
radiation have effects on certain healthy cells of the 
patient as well. Treatments which are based on specific 
molecules that target a signalling pathway in the growth 
and development of a tumor cell are called targeted 
molecular therapies (TMTs). 
Tumor growth is limited by diffusion distance, thus 
after a certain size tumor development stops in the 
absence of oxygen and nutrients. When tumor becomes 
able to form own blood vessels, it is called angiogenic 
switch. Thereby, tumor leaves premalignant stage and 
become malignant tumor, whereupon rapid tumor growth 
starts and after vascular invasion tumor can give 
metastasis in other organs [9]. 
Antiangiogenic therapy [10] is a type of TMTs, which 
inhibits angiogenesis (forming new blood vessels). 
Preventing tumor cells from grow and develop, the tumor 
can be kept in a dormant state, where the cellular 
proliferation rate balanced by the apoptotic rate, thus the 
tumor will be unable to grow in size beyond a few 
millimetres [11]. 
Obesity [12] has reached epidemic proportions in many 
countries of the developed world. For instance, since a 
long time more than the half of the United States’ 
population has overweight or is obese [13]. The situation 
is not much better in Hungary: according to the latest data 
from the OECD 34.1% of the Hungarian adult population 
has overweight, and 19.5% is obese [14]. Unfortunately 
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the same trends apply for pediatric obesity as well: 
worldwide [15] and in Hungary [16].  
Obesity is in focus of public health because it has been 
demonstrated to increase all-cause morbidity and 
mortality [17]; hence, it represents an important public 
health risk factor. Diseases that have been casually linked 
to obesity include type 2 diabetes mellitus, several 
cardiovascular diseases, asthma, etc. [18]. These have 
been described specifically in children too [19]. 
Obesity, but even overweight induces certain changes 
in laboratory parameters. Several changes are more or less 
direct consequence of the altered homeostatic equilibrium 
caused by obesity (for example the elevated levels of 
alanine transaminase and aspartate transaminase [20]). On 
the other hand, the change in certain laboratory parameters 
cannot be attributed to a single, well-defined 
pathophysiological alteration, but indicate a more complex 
process, sometimes even before the patient has any 
symptom of manifest obesity (for instance C-reactive 
protein [21]). 
The relationship between overweight/obesity and 
laboratory results was investigated empirically, based on a 
cross-sectional clinical observation. To our recent 
knowledge, there is no Hungarian database of adolescents 
which contains the necessary anthropometric, 
demographic and laboratory parameters; we organized a 
data collection specifically to address this issue. 
II. PRELIMINARY MODEL-FREE RESULTS OF THE 
DEVELOPED ROBUST CONTROL FRAMEWORK 
Last year at the INES 2012 conference we have 
summarized the validation results obtained on our robust 
control framework regarding a large set of 83 type 1 
diabetic patients [3]. 
Based on the obtained results, we went further and 
started to investigate the model-free property of the 
controller: if the originally used modified Sorensen-model 
[22] is changed to another model, how should the 
controller react without redesigning it. 
We have used the well-known model of Hovorka [23], 
and created a whole new set of virtual patients. This 
model represents the core of the in-silico simulator of the 
University of Cambridge version 2.2 (SimEdu). Using the 
results, which were collected from the insulin pump 
centers of the Hungarian Artificial Pancreas Working 
Group (MAP), these two T1DM models were used to 
generate the virtual patients. The identification was carried 
out using the Levenberg-Marquardt algorithm [24] and the 
Optimization toolbox of MATLAB. The running time has 
been greatly reduced by providing a fair estimation of the 
Jacobian matrix without the use of loops. 
Based on our preliminary results we found out that 
hypoglycaemia is still efficiently avoided and 
hyperglycaemia is reduced more than 75% to the real 
datasets if parameter identification and the starting point 
of the algorithm are well determined. Simulations were 
started 1-2 days before the start of the identification 
timeframe in order to minimize problems caused by initial 
states. However, this requires more apiori information 
from the patient side. 
Fig. 1 presents simulation results of 14 years old girl 
using insulin pump from three months, and having an 
active lifestyle and bad compliance. She is managed at 
Veszprém, Hungary, using an IPro2 glucose sensor. 






























Figure 1.  Simulation results on the model of Wilinska et al. [23]. The 
upper figure presents the comparison of robust controller output (solid 
line) and sensor real data (dashed line), while the dots represent the real 
fingertip measurements. The lower figure shows the insulin control 
input. 
It can be seen that blood glucose level could be still 
stabilized in a better range than the real data of the patient, 
while hypoglycaemia is efficiently avoided. However, the 
insulin input is not optimal anymore (compared to the 
results on the modified Sorensen model), as a bigger 
continuous value should be used, complemented with 
other boluses as well. 
In the future it is planned to make more model-free tests 
on the model of [23], but on other models as well. 
III. TUMOR GROWTH MODEL DEVELOPMENT 
A. Control design of existing tumor growth model from 
the literature 
We have investigated a simplified form of a dynamic 
model for tumor growth in antiangiogenic therapy 
introduced in [25]. Continuing our preliminary 
examinations and results in antiangiogenic tumor growth 
control [26-29], our aim was to find suboptimal, but close 
to optimal control solutions, which are cost-effective 
(angiogenic inhibitors are quite expensive, thus the goal 
of the control is to minimize the tumor volume using the 
least possible control signal). 
Solving the control problem by linearization [28], we 
have designed four controllers: state feedback with pole 
placement, LQ control method, state feedback with pole 
placement and observer, and LQ control method with 
observer. Controllers were designed for the linearized 
model, but were used for the nonlinear model. Three 
working points, three saturation values and three amount 
of acceleration were analyzed. Controllers were evaluated 
by three criteria: (i) the total concentration of the 
administered inhibitor during the treatment (mg/kg), (ii) 
the steady state inhibitor concentration at the end of the 
treatment (mg/kg), (iii) the steady state tumor volume at 
the end of the treatment (mm3). 
Simulation results were divided into seven groups. 
Three groups of controls were efficient, but not 
successful (tumor volume was reduced, but not up to the 
required volume). Two groups of controls were 
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unsuccessful. For almost every controller oscillation was 
found at the steady state inhibitor concentration, mainly 
in low working points – these controls form a group as 
well. 
The last group contains the successful control 
solution with respect of each criterion. LQ 
controllers had the best results for (i) and (ii) 
criteria, but also for (iii) criterion these controllers 
had near-optimal values. In addition, LQ control 
method was the only one, which could handle the 
problem of high working points. Therefore, we have 
investigated weighting matrix R in a wide range (R = 
[102, 106]).  
We have found that there are “typical” minimum 
locations, where each criterion has close to optimal 
values. Thus we created an optimal set of R values with 8 
elements. Since we had 3 examined saturation values, we 
got 24 optimal R value – saturation value pairs. 
Considering all three criteria, optimal R value – saturation 
value pairs, which give the best result, are summarized. 
We have found, that R = 2000, umax = 25 mg/kg and R = 
4000, umax = 25 mg/kg pairs are solutions for each 
working point, however in medium and high working 
points the steady state tumor volume is higher than the 
required value. 
Consequently, the control law can be formulated in 
two phases. In the first phase of the control, R = 2000, 
umax = 25 mg/kg or R = 4000, umax = 25 mg/kg pair have to 
be chosen. In the second phase, this control has to be 
kept, if the steady state tumor volume is optimal; 
otherwise a smaller R value has to be chosen, which 
results an optimal steady state tumor volume also in 
medium or high working points. Switching ensures that 
the control passes along optimal points considering all 
three criteria. 
B. Identification of a new tumor growth model  
We have examined tumor growth dynamics in case of 
C38 colon adenocarcinoma and B16 melanoma with 
mouse experiments. C38 tumor cells inflict strong 
hypoxial reaction and have a large relative vascular area 
[30], which is beneficial if we would like to examine the 
effect of angiogenic inhibition. B16 melanoma [31] is 
also a mouse tumor. B16 mice melanoma can be used as 
a model for human melanoma [32]. 
The simplest dynamic model is a linear one, thus the 
response of the system consists of exponentials functions. 
Antiangiogenic therapy effects on tumor vasculature, the 
inhibition of vascular system results in the reduction of 
tumor mass. Since we want to identify the dynamics 
behind tumor mass growth and vasculature growth, we 
are seeking for a second order system. 
The second order system has two exponential 
functions in its response, thus parametric identification 
was carried out by fitting a curve with two exponential 
functions. 
Exponential curve fitting for average in case of C38 
colon adenocarcinoma can be seen in Fig. 2. The 
response of the system is described by: 
y(t) = -0.076·exp(0.4239t) + 16.87·exp(0.2329t) (1) 
 
 
Figure 2.  Exponential curve fitting for average in case of C38 colon 
adenocarcinoma (y(t) = -0.076·exp(0.4239t) + 16.87·exp(0.2329t)) 
 
 
Figure 3.  Exponential curve fitting for average in the case of B16 
melanoma (y(t) = -511.6·exp(0.54781t) + 512.3·exp(0.54775t)) 
 
The time constants of the identified model are: T1 = 
2.3589 days, and T2 = 4.2938 days. The coefficients of 
the exponentials are positive, thus the system is unstable, 
as it is required from a tumor growth. 
Exponential curve fitting for average in case of B16 
melanoma can be seen in Fig. 3. The response of the 
system is described by: 
y(t) = -511.6·exp(0.54781t) + 512.3·exp(0.54775t) (2) 
The time constants of the system are T1 = 1.8256 days 
and T2 = 1.8254 days. The parametric identification 
results in almost identical time constants; however, the 
multiexponential characteristic is important. This simple 
model results in a plateau-like characteristic at high 
tumor volume values, without the nonlinear model of the 
Gompertzian growth [33]. 
The coefficients of the exponential functions are 
positive in this case as well, resulting in an unstable 
system. 
In the future we plan to formulate the created model in 
terms of control engineering, make more validation tests, 
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and design control structures similar to ours already 
presented algorithms. 
IV. BIOSTATISTICAL METHOD FOR OBESITY 
INVESTIGATION 
A. Patient Data 
We have examined 82 healthy volunteer adolescents 
(60 boys and 22 girls) and 101 patients (53 boys and 48 
girls) treated for obesity without significant comorbodity 
(Heim Pál Children’s Hospital, Budapest). Altogether our 
sample included n=183 adolescents aged between 12 and 
18 (113 boys, 70 girls). 
For the healthy volunteers, the examination consisted 
of anthropometric measurements (body height, body 
mass, hip-, waist- and left arm circumference), body 
composition analysis, recording of basic demographic 
and anamnestic data, and the drawing of a fasting blood 
sample for laboratory examination. The investigated 
subjects form a convenience sample; hence the results are 
not necessarily representative. In particular, the obese 
population was intentionally oversampled in the study 
design. 
The investigation’s research program was pre-
authorized by the Hungarian Regional Bioethical 
Committee. 
B. Statistical Analysis 
We used the well-known Body Mass Index (BMI) to 
quantify overweight/obesity. The BMI must be 
considered relatively based on age (and sex). We used z-
score, which is a standardized BMI (that is: actual BMI 
minus the reference BMI mean for the age and sex, 
divided by the standard deviation of the reference for age 
and sex), with the exception that instead of the actual 
BMI, an algebraic transform of it is used (which aims to 
normalize the distribution of BMI, so that z-score is 
interpretable) [34]. According to our knowledge, the only 
Hungarian growth chart (which is based on the National 
Longitudinal Child Growth Survey [35]) does not contain 
the parameters necessary for normalization, so we used 
the US growth chart of the Centers for Disease Control 
and Prevention (CDC) [36] to calculate the z-scores (or 
zBMI). Sexes were separately analyzed to avoid intractable 
interactions. 
The logic of the investigation is illustrated on Fig. 4 
for the white blood cell count of boys. Fig. 4a is the 
scatterplot of the investigated laboratory parameter and 
zBMI. We used the Spearman (rank)correlation coefficient 
[37], which measures the strength and direction of not 
only linear, but monotone connection in general. This 
way, we could detect potential nonlinear relationships as 
well. We considered a correlation significant if the p-
value was less than 0.05/33, that is, the significance level 
was corrected according to Bonferroni [38] to take the 
multiple comparisons situation [39] into account. 
The next problem was to define how an indicator is 
measured for a given standardized BMI (for example for 
zBMI =2). As our data are continuous, the simple 
calculations are not possible (most likely there is not a 
single patient who has exactly zBMI =2). We tried to 
reconstruct the (two-dimensional) joint distribution 
(probability density function) of zBMI and the investigated 
laboratory parameter. For that end, we used kernel 
density estimation [40] to obtain a (continuous) 
distribution based on the sample. We used normal kernel, 
the bandwidth-matrix was estimated with smoothed 
cross-validation [41]. The estimated two-dimensional 
joint probability density function is shown (with contour 
lines) in Fig. 1b. 
After this, the procedure was straightforward: from the 
joint distribution, one can simply obtain the conditional 
distribution for any zBMI (as condition), and from this 
conditional distribution, any indicator can be directly 
calculated (the average, for example, by means of 
numeric integration). For reasons of interpretability and 
robustness, we used average and median (as indicators of 
central tendency) and standard deviation and interquartile 
range (as indicators of dispersion) [42]. 
C. Data Processing 
Data was processed, and statistical analysis was carried 
out under R statistical program package (version 14.2). 
To automate the whole process, we have developed a 
script which is available at the corresponding author on 
request. 
D. Results 
These results confirm many theories that are already 
known from the literature and also raise some new 
questions. 
The level of C-reactive protein is strongly associated 
with the degree of overweight/obesity, both for boys and 
for girls. This observation is consistent with the literature: 
obesity is long considered as a systematic, ’low-grade’ 
inflammation state, even in childhood [43]. Deviations 
we identified above were else already described, 
specifically in children too [44]. 
This is supplemented by the observation that the 
haemoglobin decreases with the level of obesity 
(although not significantly after correction), with MCV 
and MCH decreasing (significantly for both sexes) – and 
in fact, chronic inflammation can cause anaemia [45]. 
The change in MCV and MCH pointed to hypochromic, 
microcytic anaemia. 
Levels of liver enzymes ALT and GGT (but not AST) 
are positively correlated with the degree of obesity 
(significant for boys). The most likely explanation for this 
is the effect of central obesity on liver function which is 
presumed to be in connection with non-alcoholic fatty 
liver disease [46], [47]. 
V. CONCLUSIONS 
The paper summarized the current research tasks in the 
field of physiological modeling and control of diseases 
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with high public health impact carried out by the recently 
formed Physiological Controls Group of the Obuda 
University. Latest results were presented in the field of 
diabetes, cancer and obesity. 
 
Figure 4.  Investigation methodology in case of obese and laboratory parameters through the white blood cells of the boys. 
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